Kallidinogenase
CAS No.: 9001-01-8 (kinin-releasing activity)

Short Description:

Source: Extracted from porcine pancreas
Function and use:Kallidinogenase is a kind of kallikrein in human tissues and mammals. It exists in the body in the form of an inactive precursor—prekallikrein, which can degrade kininogen into kinin. Kinin can dilate blood vessels and capillaries,increase vascular permeability,improve microcirculation, regulate blood pressure, and reduce myocardial oxygen consumption. This enzyme is also an activating factor, which can activate plasminogen into plasmin, hydrolyze insoluble fibrin into soluble small peptides, thereby leading to thrombolysis, and can also regulate and reduce hypertension. For a variety of heart and cerebrovascular diseases, such as essential hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal blood supply disorders and peripheral vascular disease.

Kallidinogenase-Pharmacopoeia Standard: JP

Send email to us

Product Detail

Product Tags

CAS No.: 9001-01-8
Complies with CP2020, JP18

Specification

Kallidinogenase
Source			Porcine pancreas
Process description			Kallidinogenase is an enzyme extracted from healthy porcine pancreas, and has kinin-releasing activity based on cleavage of kininogen. It contains not less than 300 kallidinogenase units(for oral use) or 600 kallidinogenase units(for injection use) per mg
Productionrequirements			This product should be extracted from porcine pancreas that has passed quarantine. Production process should conform with the requirements of current version of Good Manufacturing Practice. This product is derived from animals, and appropriate virus inactivation processes should be used for virus safety control during production
Pharmacopoeia standard			CP		JP
			for oral	for injection
Character			White or almost white powder. Odorless.It is freely soluble in water, and practically insoluble in ethanol and diethyl ether.		Description Kallidinogenase occurs as a white to light brown powder. It is odorless or has a faint, characteristic It is freely soluble in water, and practically insoluble in ethanol (95) and in diethyl ether.
Identification			The value of R should be 0.12～0.17		The value of R does not exceed 0.2
			The retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution		the value of R is between 0.12～0.16
Test	pH		5.5-7.5		5.5-7.5
	Appearance of solution		Should be clear		_______
	Purity		≥70%	≥90%	_______
	Purity	Fat	The mass of residue is not more than 5mg		The mass of residue is not more than 1mg
		Kininase	_______		The value R is not less than 0.8
		Trypsin-like substance	_______		The value of T does not exceed 0.05
		Protease	A₂₈₀≤0.2		The value of (A-A₀) not more than 0.2
	Loss on drying		≤5.0%		Not more than 2.0%
	Residue on ignition		≤3.0%		Not more than 3%
	Bacterial endotoxin		/	≤2.5 EU/IU（for injection)	_______
	Kinin-releasing activity		_______		Not less than 500ng bradykinin equivalent/minute/unit
	Total protein		Conform with regulation		_______
Potency	Enzyme activity		Conform with regulation		Not less than 25IU/mg
	Specific activity		≥300IU/mg.pr	≥ 600IU/mg.pr	Not less than 100IU/mg.pr
Microbial limit	TAMC		≤1000cfu/g		≤1000cfu/g
	TYMC		≤100cfu/g		≤100cfu/g
	Escherichia coli		Should not be detected per g		Should not be detected per g
	Salmonella		Should not be detected per 10g		Should not be detected per 10g
Storage			Protected from light, sealed, stored in a cool, dry place.		Tight containers
Category			Vasodilators.
Preparation			Kallidinogeanse enteric-coated tablets